Albeit an improved response and a lower cumulative risk of CNS progression for first-generation TKI compared to chemotherapy [23], first- and second-generation TKIs distributed poorly in the brain, partly owing to the interaction with permeability glycoprotein (P-gp) and breast cancer-resistance protein (BCRP) [24]. Here, ABCG2 is linked to cancer.